The World Health Organization (WHO) has authorized the AstraZeneca COVID-19 vaccine for emergency use.
“AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals 18 years of age and older, including those over 65.”
According to WHO, they have listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use giving the green light for the said vaccines to be rolled out globally through COVAX which was produced by:
- AstraZeneca-SKBio (Republic of Korea)
- Serum Institute of India
Furthermore, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), makes recommendations for vaccines’ use in populations, recommended the vaccine for all age groups 18 and above.
Emergency Use Listing (EUL) by WHO
The WHO’s Emergency Use Listing (EUL):
- Assesses the quality, safety, and efficacy of COVID-19 vaccines.
- A prerequisite for COVAX Facility vaccine supply.
- Also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
- WHO EUL process can be carried out quickly when vaccine developers submit the full data required by WHO in a timely manner.
According to WHO, for the EUL of the two AstraZeneca/Oxford vaccines, “WHO assessed the quality, safety and efficacy data, risk management plans and programmatic suitability, such as cold chain requirements. The process took under four weeks.”
More About AstraZeneca
AstraZeneca/Oxford product is:
- A viral vectored vaccine called ChAdOx1-S [recombinant].
- Produced at several manufacturing sites, as well as in the Republic of Korea and India.
- Found to have 63.09% efficacy and is suitable for low- and middle-income countries due to easy storage requirements.
Furthermore, more than 50 countries have granted emergency use for the AstraZeneca vaccine, and with the WHO EUL now accelerating the pathway to access in up to 145 countries through the COVAX Facility.
For More News and Updates